NIH Reporter #5R21CA282857-02

Research Services for Sonic Hedgehog Antagonist Discovery and Preclinical Evaluation

This opportunity seeks specialized research services for cancer therapeutics targeting the Sonic Hedgehog pathway: - Government Buyer: - National Cancer Institute (NCI), in partnership with the State University of New York at Binghamton, Chemistry Department - Products/Services Requested: - Research and development services focused on the discovery and preclinical evaluation of antagonists for human Sonic Hedgehog autoprocessing - High throughput screening of compounds - Preclinical anti-tumor activity assessment - OEMs and Vendors: - No specific OEMs or commercial vendors are named in the solicitation - Notable Requirements: - Expertise in high throughput screening and preclinical evaluation of anti-tumor compounds - Focus on developing first-in-class antagonists for a novel cancer therapeutic target (Sonic Hedgehog autoprocessing) - Project budget is approximately $219,881 - Classified under NAICS codes for engineering and life sciences R&D

Description

This project involves high throughput screening for antagonists of Sonic Hedgehog autoprocessing with the aim to develop targeted cancer therapeutics. It includes preclinical evaluation of identified compounds. The funding is provided by the National Cancer Institute, part of NIH. The project duration is from March 1, 2025, to February 28, 2027, with a budget of approximately $219,881.

View original listing